Arturo LoAIza-Bonilla, Systemwide Chief of Hematology and Oncology at St. Luke’s University Health Network, and Co-Founder and Chief Medical AI Officer (CMAIO) of Massive Bio, shared a post on LinkedIn:
“Honored to serve as Guest Editor for a new Special Issue in Cancers MDPI: The Use of Artificial Intelligence in Predicting Response to Cancer Therapy
If you’re preparing—or recently presented—work for ASCO, AACR, NCCN, SITC, ESMO, ASH, or leading digital pathology / AI conferences, I strongly encourage you to consider submitting your manuscript to this issue.
We are seeking rigorous, clinically grounded AI research spanning:
- Multimodal models (genomics, pathology, imaging, RWD)
- Response and resistance prediction
- Immunotherapy, targeted therapy, cell & gene therapy
- Explainable and trustworthy AI
- Real-world implementation, equity, and federated learning
- Human–AI collaboration and decision support
Why this Special Issue
- Rapid review (≈20 days to first decision)
- High visibility & discoverability (PubMed)
- Dedicated thematic focus for AI-in-oncology work
- Continuous publication upon acceptance
Submission deadline: June 29, 2026
Submit here.
Looking forward to highlighting work that moves AI in oncology from models to impact.”
More posts featuring Arturo LoAIza-Bonilla.